Centrus Energy: The Military Is the New Anchor for America's Nuclear Fuel Toll Road

Centrus Energy: The Military Is the New Anchor for America's Nuclear Fuel Toll Road

For roughly four decades, the United States did something no strategic power can responsibly do: it let its ability to enrich uranium wither, and quietly outsourced the work to the country it now spends hundreds of billions to deter. Russia's state-owned Tenex became a fixture of the American nuclear fuel supply chain, at one point supplying roughly a quarter of the enriched uranium that keeps U.S. reactors running. Politically, that dependency is over. The Prohibiting Russian Uranium Imports Act of 2024 ended it in stages, with the full ban effective January 1, 2028. And when Washington is forced to repatriate a mission-critical supply chain, it needs a domestic supplier. There is exactly one: Centrus Energy (LEU).

The most interesting part of this story is not the plan to build a big domestic enrichment plant. It is that the company's leadership is increasingly framing the U.S. government and military, not just commercial reactors, as the marquee customer. That matters more than any single reactor order, because a government buyer is the toll road every infrastructure investor dreams of: it cannot wait for the business cycle, it cannot import a substitute, and it is funded out of a defense budget rather than an economics one. This is the newest and, in my view, the most durable leg of the Centrus growth story. It is also the reason the stock is not what it looks like at first glance.

Not a Mining Company, a Toll Road

Most investors file LEU under uranium mining, which is how it is classified. That is misleading. Centrus does not dig ore out of the ground. It operates the only U.S.-owned commercial-scale uranium enrichment capability left after the federal gaseous diffusion plants were shut down in 2013. Enrichment is the industrial step where natural uranium is processed to raise its concentration of the fissionable isotope U-235; utilities buy that service in units called separative work units, or SWU. Think of the business as a toll road built on a choke point: the toll is the price of enrichment, and the road is a physical, hard-to-replicate industrial capability. No domestic enrichment, no nuclear fuel. That is the essence of a real-economy, mission-critical franchise — except this toll plaza is guarded by national security, which is a stronger fence than any moat a commercial company can build on its own.

Here is the detail that should stop a reader cold: for certain national security missions, Centrus may be the only company the U.S. government can legally use. Nonproliferation agreements bar foreign-sourced fuel for those purposes, and Centrus has laid out in its own materials that it would be the only entity able to supply U.S. government LEU for national security needs. Independent analysts add that in early 2026, the National Nuclear Security Administration issued Centrus a sole-source notification for certain classified enrichment activities. When the buyer has no legal alternative and the seller is the only domestic line, pricing power is not a matter of strategy. It is a matter of math.

The Silent Military Demand Behind the Commercial Story

The military leg also has genuine volume behind it, and it compounds the civilian case. Commercial reactors run on low-enriched uranium under 5% U-235, while the advanced small modular reactors under construction need high-assay low-enriched uranium — HALEU — enriched between 5% and 20%, a material almost nobody in the West can currently produce. But the Navy is the sleeping giant. American naval reactors have historically run on weapons-grade fuel enriched to roughly 93% U-235, a reliance that nonproliferation experts, including voices inside the U.S. government, have spent years pressing the Navy to end. A shift of new naval cores to HALEU would, for the first time, hand a large slice of the U.S. nuclear fleet's fuel demand to the private enrichment industry. That shift is not hypothetical: the Navy is simultaneously expanding its number of nuclear-powered hulls and has confirmed that its planned large surface combatant will be nuclear-powered, adding to an already stretched fuel requirement. Add military micro-reactor programs to power isolated bases, and you have a government end-market that is simultaneously price-insensitive, import-proof, and growing.

Centrus quantifies the opportunity in its own investor materials, framing future uranium enrichment for U.S. national security missions as a market of roughly $3.9 billion to $6.0 billion. Notice what that number is, and what it is not. It is a total addressable market, not a booked order. The military demand is a serious, structurally backed possibility with an enormous moat behind it — but the revenue is largely in front of the company, not behind it. That distinction is central to how an investor should judge the stock.

The Build-Out Is Underway, and It's Being Funded Before Construction Starts

The government leg sits on top of a rapidly firming commercial one. In early August the company signed a comprehensive LEU and HALEU supply agreement with X-energy, the reactor developer behind the Xe-100 small modular design and TRISO-X fuel, structured to include prepayments — non-dilutive, non-debt money that funds the enrichment build-out. That came on the heels of a $900 million Department of Energy award to move the demonstration cascade to commercial operation, a task order worth up to $1.07 billion including options, with up to $170 million reserved for HALEU purchases for departmental missions. Centrus says it has produced more than 1,900 kilograms of HALEU since the original 2019 demonstration work, finished its final 900-kilogram batch ahead of schedule, and now reports total backlog of $4.5 billion stretching into 2040 — including roughly $2.4 billion under definitive agreements backing construction at Piketon, Ohio, on top of the X-energy contract that adds to an existing $3 billion contingent LEU and HALEU backlog.

The scale of the plan is where the story stops being a demonstration project: 12 metric tons of new annual HALEU capacity, centrifuge manufacturing ramping in Oak Ridge, Tennessee, and the first new commercial capacity scheduled to come online in 2029. Management framed the demand backdrop on the latest earnings call as "healthy demand momentum" with "consistent constrained supply." For a strategist who reads leading indicators before lagging ones, that is the relevant signal: not the reactor count, but the price of the toll, and the toll is firming because the physical supply is short.

The Part I Don't Like: This Is Not an Income Stock

Now the honest check, because dividend investors are the ones who get burned by stories like this. The earnings Centrus reports today are not primarily coming from spinning centrifuges. They come from arbitrage: buying enrichment services at legacy contract prices from Russia's Tenex — contracts struck at roughly $80 to $100 per SWU — and reselling them to U.S. utilities at today's market rates of roughly $160 to $190. The LEU brokerage produced about $111 million of gross profit in 2025 on roughly $346 million of revenue, a fat margin that is really a discount on a sunsetting contract. When the Russian import ban becomes fully effective at the start of 2028, that cheap source of enrichment disappears with it. Between the end of the arbitrage windfall and the first new domestic capacity in 2029 or 2030, the company faces what independent analysis describes as a revenue and margin trough. The second quarter, reported on August 5, hinted at the transition stress: revenue rose 14% year over year to $176 million, but GAAP earnings of $0.77 per share came in well below the $1.67 the Street expected, with stock-compensation charges muddying the quarter.

Run the company through an income investor's checklist and the picture is clear: there is no dividend, and until the new capacity runs, free cash flow is negative — about $164 million over the trailing twelve months, with operating cash flow also negative and capital expenditures building the plant. The balance sheet, in contrast, is genuinely strong for a company in this position: roughly $1.9 billion of cash against about $1.7 billion of total debt, a net-cash position with a current ratio above five. Legacy pension obligations from the old USEC era are a slow drain, but they are not existential. The problem is on the other side of the ledger. The stock trades around $187, near 77 times trailing earnings and roughly 33 times forward earnings, against a heavy capital program. It is true that the whole uranium complex is expensive — Cameco, the mining giant, trades near 177 times trailing earnings and pays a sliver of a yield — so LEU is rich in a neighborhood full of rich things. That does not make it cheap.

There are two risks that keep me from treating the government anchor as a guarantee. First, appropriations: the Department of Energy's proposed FY2027 budget already excludes further funding for the old demonstration-cascade contract, and the department does not intend to exercise its remaining options under it. The $900 million award is the new vehicle, but it travels through a federal budgeting process that churns. Second, execution: building and operating a commercial centrifuge cascade at scale is something the United States has not actually done in decades, and long-lead machinery, fixed-price contracts, and a 2029 target leave genuine room for slippage.

The Verdict

So where does this leave an investor whose framework is dividend growth and income? The answer is uncomfortable but precise. The moat is real and getting stronger: this is a government-protected, mission-critical toll road on a physical choke point, with a military end-market that cannot wait, cannot import, and is budget-funded. That is the sort of franchise a real-economy investor wants exposure to over time, and it passes the pricing-power test with room to spare. But Centrus is not an income stock, and pretending otherwise is how investors get hurt. There is no yield today, free cash flow is negative, and the payoff is deferred to 2029 and beyond. The stock has already had its mania and its de-rating: it sits roughly 60% below its 52-week high near $464, is down in the low-to-mid twenties for the year, and is still up sharply over the trailing month as the military narrative reasserts itself.

That pattern matters. For a strategist who buys quality businesses when cyclical volatility inflates entry points, a real toll road that has de-rated without its franchise breaking is exactly the kind of setup worth following — but only for investors who can tolerate multi-year execution risk and no paycheck in the meantime. For income investors, the honest verdict is that this is a growth-and-execution story to track, not a dividend position to buy. Do not confuse a moat with a dividend. Here you are being paid in future cash flow and national security, not in current income — and if you need the income, the bridge to 2029 is a long one without a paycheck on the other side just yet.